Ovagen

Ovagen is a synthetic tripeptide (Glu-Asp-Leu) belonging to the Khavinson class of bioregulatory peptides from the Saint Petersburg Institute of Bioregulation and Gerontology. It is designed to target hepatic (liver) and gastrointestinal tissue through proposed peptide-DNA interactions. Ovagen complements Livagen (another liver-targeted bioregulator) with a different amino acid sequence and potentially distinct gene regulatory specificity. The Khavinson model proposes that even minimal peptide sequences like tripeptides carry tissue-targeting information through their charge distribution, hydrogen bonding patterns, and spatial conformation. Ovagen has been investigated in Russian biogerontology research examining age-related changes in hepatic function, liver tissue gene expression, and gastrointestinal epithelial homeostasis. It is one of several organ-specific short peptides in the Khavinson bioregulator family.

Ovagen has been investigated for its proposed interactions with gene regulatory regions in hepatocytes and GI tract epithelial cells. In the Khavinson bioregulatory model, the Glu-Asp-Leu sequence is proposed to penetrate cell membranes and interact with specific DNA sequences in promoter regions of tissue-expressed genes. Researchers have observed that Ovagen treatment in liver cell culture models was associated with changes in expression of hepatic function genes, including those involved in detoxification, protein synthesis, and bile acid metabolism. Studies from the Saint Petersburg group suggest that bioregulatory peptides targeting the liver may help maintain hepatocyte differentiation markers and metabolic enzyme expression. The proposed mechanism involves direct peptide-DNA interactions that influence chromatin accessibility at specific gene loci, rather than conventional cell-surface receptor signaling. Ovagen is studied alongside Livagen as part of the hepatic bioregulator class within the Khavinson system.

Hepatic Gene Expression

Khavinson et al. (2005) investigated short peptides in hepatocyte culture models, observing changes in gene expression profiles related to hepatic function and metabolism following treatment with liver-targeted bioregulatory peptides [1].

Bioregulatory Peptide Framework

Khavinson VK (2002) presented the comprehensive model for tissue-specific bioregulatory peptides, including those targeting hepatic and GI tissues [2].

Peptide-DNA Interactions

Fedoreyeva et al. (2011) demonstrated that short peptides can bind DNA sequences in vitro using fluorescence spectroscopy, supporting the proposed mechanism for bioregulatory peptide activity [3].